Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpine Immune Sciences Inc

< Previous 1 2 3 4 5 6 7 Next >
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs
Via Benzinga
Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
Alpine Immune Sciences Inc (NASDAQ: ALPN)  
Via Benzinga
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in September Investor Conferences
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences's Return On Capital Employed Overview
Benzinga Pro data, Alpine Immune Sciences (NASDAQ:ALPN) reported Q2 sales of $5.29 million. Earnings fell to a loss of $18.10 million, resulting in a 140.44% decrease from last quarter. 
Via Benzinga
Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences: Q2 Earnings Insights
  Alpine Immune Sciences (NASDAQ:ALPN) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate
Via Benzinga
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
From Alpine Immune Sciences Inc.
Via Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
From Alpine Immune Sciences, Inc.
Via Business Wire
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
Via Benzinga
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in May Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
From Alpine Immune Sciences Inc.
Via Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
From Alpine Immune Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.